Navigation Links
Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy
Date:6/24/2011

s approved in the U.S. in September 2006 as a monotherapy for the treatment of patients with EGFR-expressing mCRC after disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

The effectiveness of Vectibix as a single agent for the treatment of EGFR-expressing mCRC is based on PFS. More than half of patients who receive Vectibix monotherapy respond to treatment with an average six month PFS benefit.  Currently no data are available that demonstrate an improvement in disease-related symptoms or increased survival with Vectibix.

Retrospective subset analyses of mCRC trials have not shown a treatment benefit for Vectibix in patients whose tumors had KRAS mutations in codon 12 or 13. Use of Vectibix is not recommended for the treatment of mCRC with these mutations.(ix)

In December 2007, the European Commission granted a conditional marketing authorization for Vectibix as a monotherapy for the treatment of patients with EGFR-expressing mCRC with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.(x)  Vectibix has been launched in more than 30 European countries, Russia, Israel, Australia, Canada and Japan. Applications in the rest of the world are pending.

Important U.S. Product Safety Information

WARNING: DERMATOLOGIC TOXICITY and INFUSION REACTIONS

Dermatologic Toxicity: Dermatologic toxicities occurred in 89 percent of patients and were severe (NCI-CTC grade 3 or higher) in 12 percent of patients receiving Vectibix monotherapy. [See Dosage and Administration (2.1), Warnings and Precautions (5.1), and Adverse Reactions (6.1)].

Infusion Reactions: Severe infusion reactions occurred in approximately one percent of patients. Fatal infusion reactions occurred in postmarketing experience [See Dosage and Administration (2.1), Warnings and P
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 New ... most innovative thought leaders of the medical device ... East conference and expo, from June 18-20 in ... (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) , ... deliver industry professionals practical presentations and implementable solutions ...
(Date:5/17/2013)...  Yongye International, Inc. (NASDAQ: YONG ) ... distributor of crop nutrient products in the ... on May 16, 2013, the special committee (the "Special ... Directors") was provided a letter (the "Letter") issued by ... Limited ("Abax") to Full Alliance International Limited ("Full Alliance"). ...
(Date:5/17/2013)... 2013  Insero Health, Inc., a company developing natural ... related neurological disorders, is today reporting top-line results from ... in patients with drug-resistant epilepsy.  The data are being ... Xll meeting by Dr. Steven Schachter ... Scientific Advisory Board.  In this study, INS001 appeared safe ...
(Date:5/17/2013)... The paradigm of ‘one drug, one ... can help predict the adverse and therapeutic effects of ... of Computational Biology at the Genomics Laboratory, Covance, will ... high-quality genomics when used as part of the QC ... data sets to identify key clinical targets even in ...
Breaking Biology Technology:MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced ... Officer of Alexion,Pharmaceuticals, will present at the William ... 9:10 a.m., local time (10:10 a.m., eastern) on,Thursday, ... Mr. Sinha,s remarks will be available live. You ...
... Beckman,Coulter, Inc. (NYSE: BEC ), a leading ... and innovate complex biomedical tests,announces upcoming company presentations ... (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ), ... July 25, 2008., -- July 28 - ...
... Universities of Cambridge and Bristol have revealed that the ... the vacuum of a mass spectrometer. Their research ... Express . , The researchers were surprised to discover ... always been assumed that they would not survive once ...
Cached Biology Technology:Upcoming Beckman Coulter Investor Events Second Half of 2008 2Membrane complexes take flight 2
(Date:5/18/2013)... 18, 2013) Research presented today at Digestive Disease ... with findings about the impact of coffee on autoimmune ... While coffee consumption recently has been associated with reduced ... a few more cups of java each month also ... disease. Researchers at the Mayo Clinic, Rochester, MN, linked ...
(Date:5/18/2013)... 2013) Research presented at Digestive Disease Week ... through diet and lifestyle. , Individuals suffering ... muscle strength, fatigue and poor quality of life. ... in remission. A randomized, double blind, placebo-controlled study ... supplementation corresponded to significant relief of these symptoms. ...
(Date:5/18/2013)... 18, 2013) An increasing number of U.S. ... to resolve, according to research presented at Digestive ... targeting obesity, researchers at the Cleveland Clinic Children,s ... pattern of exhaled breath compared to their lean ... compound levels that can be correlated to potential ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3
... A global collaborative has produced a first draft ... that will lead to insights in agriculture, medicine, conservation ... farm at the University of Illinois will now be ... had their genomes sequenced. Researchers will announce the achievement ...
... / - PDC Biotech GmbH (PDC) today announced the ... Verwaltungs AG (Munich) and Edmond de Rothschild Investment Partners (Paris) co-led ... used to complete preclinical work and the first clinical study of ... for the treatment of preterm labour and primary dysmenorrhea . ...
... 2009) -- A husband and wife team of American paleontologists has ... ago during the early Cretaceous of central Montana. The new ... of the Canadian Journal of Earth Sciences . Ankylosaurs are ... a plate-like armour with two sets of sharp spikes on each ...
Cached Biology News:First draft of the pig: Researchers sequence swine genome 2First draft of the pig: Researchers sequence swine genome 3PDC Biotech GmbH Announces Close of Series A Financing 2PDC Biotech GmbH Announces Close of Series A Financing 3New dinosaur species from Montana 2
... Hormone Receptor 2 ( Abpromise ... Antigen: Synthetic peptide: AFRHCNPNGTWDFMHSLN, ... of Human Parathyroid Hormone Receptor 2 ... 5746 Swiss ...
BKBeta2 potassium channel Antigen: Fusion protein amino acids 1-41 (N-terminus) and 218-235 (C-terminus) of mouse BKBeta2 Accession Number: Q9CZM9...
... II inhibitor (IC50 = 59.2 M). ... H 32 O 13 MolWeight: ... RT CAS: ... Soluble to 100 mM in DMSO ...
amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2...
Biology Products: